APLS APELLIS PHARMACEUTICALS INC

Ownership history in Bayesian Capital Management, LP  ·  8 quarters on record

This page tracks every 13F SEC filing in which Bayesian Capital Management, LP reported a position in APELLIS PHARMACEUTICALS INC (APLS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.15% (2023 Q1)
Avg. % of fund
0.11%
First filed
2022 Q1
Last filed
2025 Q3
Quarters held
8
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 25,500 -12,400 -32.7% 0.12% $577K $22.63
2025 Q1 ADDED 37,900 +6,700 +21.5% 0.14% $829K $21.87
2024 Q3 ADDED 31,200 +13,925 +80.6% 0.11% $900K $28.84
2023 Q4 ADDED 17,275 +8,151 +89.3% 0.11% $1.0M $59.86
2023 Q2 REDUCED 9,124 -8,800 -49.1% 0.09% $831K $91.10
2023 Q1 ADDED 17,924 +6,324 +54.5% 0.15% $1.2M $65.96
2022 Q2 REDUCED 11,600 -2,400 -17.1% 0.10% $525K $45.22
2022 Q1 INITIATED 14,000 0.11% $711K $50.81
% of Fund (quarterly)    APLS price (monthly, adj. close)
← Back to Bayesian Capital Management, LP Holdings